Autoantibodies against complement factor H (CFH), the key regulator of alternative complement pathway, have been described as being response for atypical hemolytic and uremic syndrome (aHUS) [23], as well as being implicated in the development of C3 glomerulopathies (C3G) [24]. This evidence concerns the gene CFH and atypical hemolytic-uremic syndrome.